These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Impact of high-dose atorvastatin therapy and clinical risk factors on incident aortic valve stenosis in patients with cardiovascular disease (from TNT, IDEAL, and SPARCL). Arsenault BJ; Boekholdt SM; Mora S; DeMicco DA; Bao W; Tardif JC; Amarenco P; Pedersen T; Barter P; Waters DD Am J Cardiol; 2014 Apr; 113(8):1378-82. PubMed ID: 24582532 [TBL] [Abstract][Full Text] [Related]
24. [Statins and stroke]. Fernández Fernández FJ; Caínzos Romero T; Pía Iglesias G; Sesma P Med Clin (Barc); 2008 Oct; 131(14):559. PubMed ID: 19080833 [No Abstract] [Full Text] [Related]
25. Stenting for symptomatic intracranial arterial stenosis in China: 1-year outcome of a multicentre registry study. Ma N; Zhang Y; Shuai J; Jiang C; Zhu Q; Chen K; Liu L; Li B; Shi X; Gao L; Liu Y; Wang F; Li Y; Liu T; Zheng H; Mo D; Gao F; Wang Y; Wang Y; Feng L; Miao Z Stroke Vasc Neurol; 2018 Sep; 3(3):176-184. PubMed ID: 30294474 [TBL] [Abstract][Full Text] [Related]
26. Effect of statin on progression of symptomatic intracranial atherosclerosis. Kim HJ; Kim EK; Kwon SU; Kim JS; Kang DW Can J Neurol Sci; 2012 Nov; 39(6):801-6. PubMed ID: 23041401 [TBL] [Abstract][Full Text] [Related]
28. Safety and efficacy of ezetimibe added to atorvastatin versus up titration of atorvastatin to 40 mg in Patients > or = 65 years of age (from the ZETia in the ELDerly [ZETELD] study). Zieve F; Wenger NK; Ben-Yehuda O; Constance C; Bird S; Lee R; Hanson ME; Jones-Burton C; Tershakovec AM Am J Cardiol; 2010 Mar; 105(5):656-63. PubMed ID: 20185012 [TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of combination antiplatelet therapies in patients with symptomatic intracranial atherosclerotic stenosis. Kwon SU; Hong KS; Kang DW; Park JM; Lee JH; Cho YJ; Yu KH; Koo JS; Wong KS; Lee SH; Lee KB; Kim DE; Jeong SW; Bae HJ; Lee BC; Han MK; Rha JH; Kim HY; Mok VC; Lee YS; Kim GM; Suwanwela NC; Yun SC; Nah HW; Kim JS Stroke; 2011 Oct; 42(10):2883-90. PubMed ID: 21799173 [TBL] [Abstract][Full Text] [Related]
30. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial. Murphy SA; Cannon CP; Wiviott SD; McCabe CH; Braunwald E J Am Coll Cardiol; 2009 Dec; 54(25):2358-62. PubMed ID: 20082923 [TBL] [Abstract][Full Text] [Related]
31. An assessment of the efficacy of atorvastatin in treating patients with dyslipidaemia to target LDL-cholesterol goals: the atorvastatin matrix study. McVey D; Patel H; Eminton Z; Maton S Int J Clin Pract; 1999; 53(7):509-13. PubMed ID: 10692735 [TBL] [Abstract][Full Text] [Related]
33. Management of patients with symptomatic intracranial atherosclerosis. Leung TW; Kwon SU; Wong KS Int J Stroke; 2006 Feb; 1(1):20-5. PubMed ID: 18706064 [TBL] [Abstract][Full Text] [Related]
34. Comparison of the effects of combination atorvastatin (40 mg) + ezetimibe (10 mg) versus atorvastatin (40 mg) alone on secretory phospholipase A2 activity in patients with stable coronary artery disease or coronary artery disease equivalent. Azar M; Valentin E; Badaoui G; Kassab R; Sarkis A; Azar RR Am J Cardiol; 2011 Jun; 107(11):1571-4. PubMed ID: 21439529 [TBL] [Abstract][Full Text] [Related]
35. Atorvastatin and quinapril inhibit blood coagulation in patients with coronary artery disease following 28 days of therapy. Undas A; Brummel-Ziedins KE; Potaczek DP; Stobierska-Dzierzek B; Bryniarski L; Szczeklik A; Mann KG J Thromb Haemost; 2006 Nov; 4(11):2397-404. PubMed ID: 16907931 [TBL] [Abstract][Full Text] [Related]
36. Intracranial and systemic atherosclerosis in the NAVIGATE ESUS trial: Recurrent stroke risk and response to antithrombotic therapy. Ameriso SF; Amarenco P; Pearce LA; Perera KS; Ntaios G; Lang W; Bereczki D; Uchiyama S; Kasner SE; Yoon BW; Lavados P; Firstenfeld A; Mikulik R; Povedano GP; Ferrari J; Mundl H; Berkowitz SD; Connolly SJ; Hart RG J Stroke Cerebrovasc Dis; 2020 Aug; 29(8):104936. PubMed ID: 32689594 [TBL] [Abstract][Full Text] [Related]
37. Aggressive lipid-lowering is more effective than moderate lipid-lowering treatment in carotid plaque stabilization. Kadoglou NP; Sailer N; Moumtzouoglou A; Kapelouzou A; Gerasimidis T; Liapis CD J Vasc Surg; 2010 Jan; 51(1):114-21. PubMed ID: 19837545 [TBL] [Abstract][Full Text] [Related]
38. Cerebrovascular disease and statins: a potential addition to the therapeutic armamentarium for stroke prevention. Callahan A Am J Cardiol; 2001 Oct; 88(7B):33J-37J. PubMed ID: 11595197 [TBL] [Abstract][Full Text] [Related]
39. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Goldstein MR; Mascitelli L; Pezzetta F Neurology; 2009 Apr; 72(16):1448; author reply 1448-9. PubMed ID: 19380709 [No Abstract] [Full Text] [Related]
40. Six-month follow-up study in patients with symptomatic intracranial arterial stenosis. Asil T; Balci K; Uzunca I; Kerimoglu M; Utku U J Clin Neurosci; 2006 Nov; 13(9):913-6. PubMed ID: 17049246 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]